State Street Corp Syndax Pharmaceuticals Inc Transaction History

State Street Corp

$2.41 Trillion
Q3 2024

A detailed history of State Street Corp transactions in Syndax Pharmaceuticals Inc stock. As of the latest transaction made, State Street Corp holds 3,770,826 shares of SNDX stock, worth $52 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,770,826

Previous 3,622,335 4.1%

Holding current value

$52 Million

Previous $74.4 Million 2.39%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$17.93 - $24.81 $2.66 Million - $3.68 Million	148,491 Added 4.1%	3,770,826 $72.6 Million
Q2 2024 Aug 14, 2024	SELL	$18.82 - $23.79 $22.5 Million - $28.5 Million	-1,197,259 Reduced 24.84%	3,622,335 $74.4 Million
Q1 2024 May 15, 2024	SELL	$19.71 - $24.57 $3.88 Million - $4.83 Million	-196,630 Reduced 3.92%	4,819,594 $115 Million
Q4 2023 Feb 14, 2024	BUY	$11.39 - $21.67 $16.1 Million - $30.7 Million	1,415,576 Added 39.31%	5,016,224 $108 Million
Q3 2023 Nov 14, 2023	SELL	$14.52 - $21.77 $8.04 Million - $12 Million	-553,413 Reduced 13.32%	3,600,648 $52.3 Million
Q2 2023 Aug 14, 2023	BUY	$19.35 - $22.31 $5.57 Million - $6.42 Million	287,831 Added 7.44%	4,154,061 $86.9 Million
Q1 2023 May 15, 2023	BUY	$20.66 - $28.98 $4.5 Million - $6.31 Million	217,767 Added 5.97%	3,866,230 $81.7 Million
Q4 2022 Feb 14, 2023	BUY	$20.64 - $26.24 $21.3 Million - $27.1 Million	1,031,026 Added 39.39%	3,648,463 $92.9 Million
Q3 2022 Nov 15, 2022	BUY	$18.51 - $24.79 $3.37 Million - $4.51 Million	181,920 Added 7.47%	2,617,437 $62.9 Million
Q2 2022 Aug 15, 2022	BUY	$13.64 - $19.48 $752,655 - $1.07 Million	55,180 Added 2.32%	2,435,517 $46.9 Million
Q1 2022 May 16, 2022	SELL	$14.84 - $22.15 $1.48 Million - $2.21 Million	-99,867 Reduced 4.03%	2,380,337 $41.4 Million
Q4 2021 Feb 14, 2022	BUY	$15.23 - $22.47 $5.74 Million - $8.47 Million	376,757 Added 17.91%	2,480,204 $54.3 Million
Q3 2021 Nov 15, 2021	SELL	$13.87 - $19.8 $14.8 Million - $21.1 Million	-1,066,985 Reduced 33.65%	2,103,447 $40.2 Million
Q2 2021 Aug 16, 2021	BUY	$13.42 - $25.18 $6.94 Million - $13 Million	516,961 Added 19.48%	3,170,432 $54.4 Million
Q1 2021 May 17, 2021	BUY	$19.28 - $24.59 $18.4 Million - $23.5 Million	953,751 Added 56.11%	2,653,471 $59.3 Million
Q4 2020 Feb 16, 2021	BUY	$15.1 - $26.44 $8.77 Million - $15.4 Million	581,000 Added 51.93%	1,699,720 $37.8 Million
Q3 2020 Nov 10, 2020	BUY	$13.39 - $17.48 $8.64 Million - $11.3 Million	645,600 Added 136.46%	1,118,720 $16.5 Million
Q2 2020 Aug 14, 2020	BUY	$8.94 - $20.98 $296,968 - $696,913	33,218 Added 7.55%	473,120 $7.01 Million
Q1 2020 May 11, 2020	BUY	$6.65 - $12.03 $2.93 Million - $5.29 Million	439,902 New	439,902 $4.83 Million

Others Institutions Holding SNDX

# of Institutions

228

Shares Held

88.4M

Call Options Held

1.01M

Put Options Held

692K

View Full List

About Syndax Pharmaceuticals Inc

Ticker SNDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,565,200
Market Cap $780M
Description
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin...

More about SNDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.

Account

State Street Corp Syndax Pharmaceuticals Inc Transaction History